Kubo M - Search Results

1

Increased transcriptional activities of transforming growth factor beta receptors in scleroderma fibroblasts.

Yamane K, Ihn H, Kubo M, Tamaki K. Yamane K, et al. Among authors: kubo m. Arthritis Rheum. 2002 Sep;46(9):2421-8. doi: 10.1002/art.10477. Arthritis Rheum. 2002. PMID: 12355490 Free article.

2

IL-4 up-regulates the expression of tissue inhibitor of metalloproteinase-2 in dermal fibroblasts via the p38 mitogen-activated protein kinase dependent pathway.

Ihn H, Yamane K, Asano Y, Kubo M, Tamaki K. Ihn H, et al. Among authors: kubo m. J Immunol. 2002 Feb 15;168(4):1895-902. doi: 10.4049/jimmunol.168.4.1895. J Immunol. 2002. PMID: 11823524

3

Specific inhibition of human skin fibroblast chemotaxis to platelet-derived growth factor A-chain homodimer by transforming growth factor-beta1.

Soma Y, Mizoguchi M, Yamane K, Yazawa N, Kubo M, Ihn H, Kikuchi K, Tamaki K. Soma Y, et al. Among authors: kubo m. Arch Dermatol Res. 2002 Feb;293(12):609-13. doi: 10.1007/s00403-001-0279-6. Epub 2002 Jan 23. Arch Dermatol Res. 2002. PMID: 11875643

4

Upregulated expression of transforming growth factor-beta receptors in dermal fibroblasts of skin sections from patients with systemic sclerosis.

Kubo M, Ihn H, Yamane K, Tamaki K. Kubo M, et al. J Rheumatol. 2002 Dec;29(12):2558-64. J Rheumatol. 2002. PMID: 12465152

5

Impaired Smad7-Smurf-mediated negative regulation of TGF-beta signaling in scleroderma fibroblasts.

Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Asano Y, et al. Among authors: kubo m. J Clin Invest. 2004 Jan;113(2):253-64. doi: 10.1172/JCI16269. J Clin Invest. 2004. PMID: 14722617 Free PMC article.

6

Increased expression levels of integrin alphavbeta5 on scleroderma fibroblasts.

Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Asano Y, et al. Among authors: kubo m. Am J Pathol. 2004 Apr;164(4):1275-92. doi: 10.1016/s0002-9440(10)63215-4. Am J Pathol. 2004. PMID: 15039216 Free PMC article.

7

Prevalence of 52-kd and 60-kd Ro/SS-A autoantibodies in Japanese patients with polymyositis/dermatomyositis.

Kubo M, Ihn H, Asano Y, Yamane K, Yazawa N, Tamaki K. Kubo M, et al. J Am Acad Dermatol. 2002 Jul;47(1):148-51. doi: 10.1067/mjd.2002.121037. J Am Acad Dermatol. 2002. PMID: 12077598

8

The prevalence and clinical significance of anti-U1 RNA antibodies in patients with systemic sclerosis.

Asano Y, Ihn H, Yamane K, Kubo M, Tamaki K. Asano Y, et al. Among authors: kubo m. J Invest Dermatol. 2003 Feb;120(2):204-10. doi: 10.1046/j.1523-1747.2003.12028.x. J Invest Dermatol. 2003. PMID: 12542523 Free article.

9

Clinical features of scleroderma patients with contracture of phalanges.

Ashida R, Ihn H, Mimura Y, Jinnin M, Asano Y, Kubo M, Tamaki K. Ashida R, et al. Among authors: kubo m. Clin Rheumatol. 2007 Aug;26(8):1275-7. doi: 10.1007/s10067-006-0490-0. Epub 2006 Dec 15. Clin Rheumatol. 2007. PMID: 17171315

10

Serum levels of soluble CD21 in patients with systemic sclerosis.

Tomita M, Kadono T, Yazawa N, Kawashima T, Tamaki Z, Ashida R, Ohmatsu H, Asano Y, Sugaya M, Kubo M, Ihn H, Tamaki K, Sato S. Tomita M, et al. Among authors: kubo m. Rheumatol Int. 2012 Feb;32(2):317-21. doi: 10.1007/s00296-010-1610-3. Epub 2010 Oct 30. Rheumatol Int. 2012. PMID: 21052675

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,749 results

Search Page

Filters